Although nucleic acid drugs have shown good application prospects in the treatment of diseases, there are still many challenges in the clinical application of nucleic acids as drugs. First of all, after nucleic acid drugs enter the body, they are easily degraded by ribonucleases in the blood or cells, resulting in a short half-life; Trapped by the reticuloendothelial system (RES), resulting in a very limited number of target cells, or easy to be cleared by intracellular lysosomes after reaching target cells; in addition, whether nucleic acid drugs entering cells can escape from lysosomes The release and successful release from the carrier are also key issues affecting the effect of nucleic acid drugs. Therefore, in the development of nucleic acid drugs, it is necessary to develop in vivo nucleic acid delivery vectors that can efficiently deliver nucleic acid drugs to specific target cells, mediate the effects of nucleic acid drugs, and reduce the impact on other cells.

Figure 1. The ideal nanoparticle of nucleic acid-delivery system.( Wei X, et al.; 2019)

Currently commonly used nucleic acid delivery systems can be divided into viral and non-viral delivery systems. Viral delivery systems include retroviral vectors, adenoviral vectors, and lentiviral vectors, etc., by encapsulating nucleic acid substances into viral shells, using the molecular mechanism that the virus can transmit its genome into other cells for infection to achieve high efficiency for specific cells , Stable transfection. Viral vectors have the advantage of high transfection efficiency, which can even reach 100%, but they have the disadvantages of limited nucleic acid loading, potential gene mutation, and safety issues such as immunogenicity.

Non-viral nucleic acid delivery systems mainly include cationic liposomes, cationic polymers, and inorganic nanoparticles, which can be combined with nucleic acid molecules by encapsulation, electrostatic adsorption, and covalent linkage. Compared with viral vectors, non-viral vectors have the advantages of low immunogenicity, unlimited nucleic acid loading, and easy surface modification, and thus become one of the research hotspots in related fields.

In order to achieve good nucleic acid delivery effect in vivo, CD BioSciences offers different in vivo delivery systems based on carrier materials to meet various needs of nucleic acid delivery.

CD BioSciences provides customized delivery strategies, through the precise design and modification of delivery vehicles, as well as advanced technology platforms, can help you solve:

• There is no efficient way to deliver nucleic acids into the cells of specific tissues and organs in the body;
• Since nucleic acid molecules are negatively charged, they cannot easily cross cell membranes
• Low payload for in vivo delivery systems
• Nucleic acid molecules are diluted and degraded during in vivo delivery without protection
• Uncontrolled release of nucleic acids in vivo
• ETC……

Key Features

Viral Delivery System

• Retroviral Vector
• Adenoviral Vector
• Lentiviral Vector
• ETC……

Organic Nanoparticle Carrier

• Liposomes: Positive, Neutral and Negative Liposomes
• Chitosan and its derivatives
• Cyclodextrin
• Dendrimers
• ETC……

Inorganic Nanoparticle Carrier

• Quantum Dot
• Silicon Nanoparticles
• Carbon Nanotubes
• Iron Oxide Particles
• Metal Nanoparticles
• ETC……

Our Advantage:

• CD BioSciences Can provide professional nucleic acid in vivo delivery system to achieve efficient in vivo delivery;
• Our delivery system can add modified ligands to achieve targeting;
• The in vivo nucleic acid delivery system has low toxicity to the body and is safe to use
• In vivo nucleic acid delivery system carriers protect nucleic acid from dilution and degradation during in vivo delivery
• The delivery system can achieve timing, location, fixed rate and targeted release in vivo, so that experimental animals have a long-lasting effect after a single injection
• The system load is high, and the delivery requirements of different doses can be fulfilled
• Professional design and service team to provide you with reliable service and technical support feedback technical report in time

CD BioSciences is focused on developing in vivo delivery systems using our core technologies. With our high-quality products and services, your delivery effect will be greatly improved. If you can't find the perfect in vivo delivery system, you can contact us. We can provide one-to-one personal customization services.

References

1. Funhoff AM, et al.; Polymer side-chain degradation as a tool to control the destabilization of polyplexes. Pharm Res. 2004, 21,170-6.
2. Luten J, et al.; Methacry lamide polymers with hydrolysis-sensitive cationic side groups as degradable genecarriers. Bioconjug Chem. 2006. 17, 1077-84.
3. De Wolf HK, et al.; Biodegradable, cationic methacry lamide-based polymers for gene delivery to ovarian cancer cells in mice. Mol Pharm. 2008, 5, 349-57.
4. Angela K. Pannier, et al.; Controlled Release Systems for DNA Delivery. Molecular Therapy. 2004, 10, 1.
5. Ochiya T, et al.; New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med. 1999, 5, 707-10.
6. Wei X, et al.; Opportunities and challenges in the nanoparticles for nucleic acid therapeutics: the first approval of an RNAi nanoparticle for treatment of a rare disease. Natl Sci Rev. 2019, 6(6):1105-1106.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.